Viridian Therapeutics, Inc. (FRA:1S1)
26.49
-0.44 (-1.63%)
At close: Dec 19, 2025
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
€421,912
Profits / Employee
€1,462,130
Market Cap
2.60B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 143 | 49 | 52.13% |
| Dec 31, 2023 | 94 | 8 | 9.30% |
| Dec 31, 2022 | 86 | 36 | 72.00% |
| Dec 31, 2021 | 50 | 23 | 85.19% |
| Dec 31, 2020 | 27 | -19 | -41.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Deutsche Post AG | 573,964 |
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
Viridian Therapeutics News
- 6 days ago - Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus
- 6 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 6 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 11 days ago - VRDN: Wedbush Raises Price Target to $47 While Maintaining Outperform Rating | VRDN Stock News - GuruFocus
- 17 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN ... - GuruFocus
- 27 days ago - Truist Securities Initiates Coverage on VRDN with Buy Rating | VRDN Stock News - GuruFocus
- 6 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Wallstreet:Online